Brickell Biotech

Brickell Biotech ROE

Delisted

The Return on Equity (ROE) of Brickell Biotech (BBI) as of Nov 5, 2026 is -293.33 %. In the previous year, Return on Equity (ROE) was -158.76 % — a change of 84.76% (lower).

ROE

-293.33 %

YoY

84.76%

Last updated:

In 2022, Brickell Biotech's return on equity (ROE) was -293.33 %, a 84.76% increase from the -158.76 % ROE in the previous year.

The Brickell Biotech ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-20.35 USD
Jan 1, 2016
-19.88 USD
Jan 1, 2017
-20.38 USD
Jan 1, 2018
-33.33 USD
Jan 1, 2019
-315.25 USD
Jan 1, 2020
-77.07 USD
Jan 1, 2021
-158.76 USD
Jan 1, 2022
-293.33 USD
The Brickell Biotech ROE history
YEARROEYoY
-293.33 %+84.76%
-158.76 %+106.00%
-77.07 %-75.55%
-315.25 %+845.77%
-33.33 %+63.52%
-20.38 %+2.55%
-19.88 %-2.32%
-20.35 %-35.93%
-31.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Brickell Biotech Stock analysis

What does Brickell Biotech do? Brickell Biotech Inc is a biopharmaceutical company that focuses on the development and marketing of innovative dermatology products. The company was founded in 2009 and is headquartered in Boulder, Colorado (USA), with branches in California and Singapore. The history of Brickell Biotech dates back to the 1960s when the company was originally founded under the name Brickell Research Inc. Over the following decades, the company specialized in biological research and conducted important research that forms the basis for today's product development. Brickell Biotech's business model is based on the creation of new and innovative therapies for the treatment of various dermatological diseases. In recent years, the company has entered into a number of important partnerships to accelerate its product development and strengthen its position in the industry. Brickell Biotech operates in two main areas: pharmaceuticals and cosmetic products. In the pharmaceuticals area, the company has a number of promising therapies in the pipeline that target the treatment of skin cancer, psoriasis, and other dermatological conditions. The company's flagship product is Sofpironium Bromide, a potential treatment for hyperhidrosis (excessive sweating). In the cosmetic products area, the company has developed a range of skincare products tailored to the needs of people with sensitive, dry, or aging skin. These products include moisturizers, cleansers, and anti-aging products, all made from high-quality ingredients. Brickell Biotech works closely with the scientific community to explore the latest developments and innovations in dermatology and the cosmetics industry. The company has also established a strong presence in the medical and research sectors by collaborating closely with leading universities and medical institutions worldwide. Overall, Brickell Biotech is a promising company in the biopharmaceutical and cosmetics industry, specializing in the development of new and innovative therapies for the treatment of skin conditions. With a strong pipeline of products and a dedicated leadership team, the company is expected to continue growing and establish itself as an important player in the industry. Brickell Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding Brickell Biotech's Return on Equity (ROE)

Brickell Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Brickell Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Brickell Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Brickell Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Brickell Biotech stock

Return on Equity (ROE) of Brickell Biotech is -293.33 % in 2022.

Return on Equity (ROE) of Brickell Biotech changed from -158.76 % to -293.33 %, representing a 84.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Brickell Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Brickell Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Brickell Biotech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Brickell Biotech